Effect of Camel Milk With Probiotic on Type 2 Diabetes Mellitus
NCT ID: NCT04296825
Last Updated: 2020-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2018-06-01
2018-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Glycaemic and Insulinaemic Responses of Camel Milk
NCT01498523
Effect of Camel Milk on Insulin and Incretin Response
NCT03725969
Effect of Milk Consumption on Glycemia and Gut Microbiome in T2D
NCT05294861
Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes
NCT02728414
Effect of Triticale, Mung Bean and Adzuki Bean Intervention on Patients With Type 2 Diabetes
NCT02999867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P
Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
Cow milk
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
CA
Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
Camel milk containing Bifidobacterium animalis A6
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
C
Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
Camel milk
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
A
Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
Bifidobacterium animalis A6
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Camel milk containing Bifidobacterium animalis A6
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Camel milk
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Bifidobacterium animalis A6
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Cow milk
Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who diagnosed as type 2 diabetes
* Agree to take the products to be studied during the study period, and no longer take other fermented dairy products (live lactic acid bacteria drinks, cheese, yogurt, probiotic products, etc.) and antibiotic
* Agree to sign the informed consent form
Exclusion Criteria
* Have serious allergic reaction to skim milk powder or milk
* Researcher are not sure whether the subjects are willing or able to complete the study
* Subject had other serious diseases
35 Years
68 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Chinese Medicine Hospital-Pinggu Hospital
UNKNOWN
China Agricultural University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fazheng Ren
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chinese Medicine Hospital Pinggu Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Auer HE, Doty P. The synthesis, structure, and optical properties of some copolypeptides containing nonpolar amino acid residues. Biochemistry. 1966 May;5(5):1708-15. doi: 10.1021/bi00869a037. No abstract available.
Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, Panwar RB, Sahani MS. Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan, India. Diabetes Res Clin Pract. 2007 May;76(2):290-6. doi: 10.1016/j.diabres.2006.09.036. Epub 2006 Nov 13.
Saigusa M, Mizuno A, Morimoto K, Nakamura K. [Acute postoperative renal failure due to extracorporeal circulation--with reference to the evaluation of fatal cases]. Kyobu Geka. 1967 Sep;20(9):594-9. No abstract available. Japanese.
Casini F, Sbarigia V, Schiavone C. [Identification of Cannabis indica in the residues of incomplete combustion of the drug]. Boll Chim Farm. 1969 May;108(5):330-6. No abstract available. Italian.
Baumgarten A, Melrose GJ, Vagg WJ. Continuous recording of dermal exudative reactions. Dermatologica. 1970;140(4):219-24. doi: 10.1159/000252557. No abstract available.
Burdon JF. [Medicine in Great Britain]. Concours Med. 1965 Oct 9;87(41):5799-803. No abstract available. French.
Lavin MF, Seymour GJ. Reduced levels of fibronectin in ataxia-telangiectasia lymphoblastoid cells. Int J Cancer. 1984 Mar 15;33(3):359-63. doi: 10.1002/ijc.2910330313.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDLT2DM-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.